Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Transitional Cell 4Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Merkel Cell 2Breast Neoplasms 2Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Chordoma 1

Interventions

Sunitinib 3Radiotherapy 3Cryosurgery 3pembrolizumab 2fludarabine phosphate 2Peripheral Blood Stem Cell Transplantation 2Nephrectomy 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2siltuximab 1avelumab 1Thalidomide 1Tacrolimus 1Suspensions 1Radiosurgery 1Radiofrequency Ablation 1Propranolol 1Powders 1PT-100 dipeptide 1Mycophenolic Acid 1Iodine 1Introns 1Interleukin-2 1Immunohistochemistry 1Genistein 1Gene Expression Profiling 1G250 monoclonal antibody 1Flow Cytometry 1Etoposide 1Docetaxel 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Kidney Neoplasms × avelumab × Clear all
NCT03035630 2022-02-15

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡